Literature DB >> 17696240

Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation.

Tatsuki Ichikawa1, Kazuhiko Nakao, Keisuke Hamasaki, Takuya Honda, Hidetaka Shibata, Mana Akahoshi, Susumu Eguchi, Mitsuhisa Takatsuki, Takashi Kanematsu, Katsumi Eguchi.   

Abstract

Interferon (IFN) therapy is the only treatment strategy for hepatitis C virus (HCV) infection after liver transplantation (LT), but prophylactic and treatable IFN therapy after LT has been shown to be insufficient due to the adverse effects of IFN and rivabirin. In this paper, we describe the disappearance of HCV after LT without IFN therapy in the presence of residual viremia on the day of LT. We herein report our findings since this is considered an important case for the anti-HCV strategy of post LT. A 60-year old woman with LC and HCC was referred to Nagasaki University Hospital in August 2004. After she underwent LT on February 18, 2005, we injected peg-IFN-alpha-2a the 11th time at 18 wk and HCV-RNA was still positive in the serum at LT. The serum HCV-RNA was negative one month after operation and subsequently dissolved 15 mo after operation without IFN therapy. As a result, we speculate that if HCV-RNA is positive while HCV core antigen is negative before LT, then it may lead to clearance of HCV after LT. Therefore long acting peg-IFN-alpha-2a is thus considered a potentially effective agent for the treatment of HCV-related cirrhosis before LT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696240      PMCID: PMC4205323          DOI: 10.3748/wjg.v13.i30.4149

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.

Authors:  Naga Chalasani; Cosme Manzarbeitia; Peter Ferenci; Wolfgang Vogel; Robert J Fontana; Michael Voigt; Caroline Riely; Paul Martin; Lewis Teperman; James Jiao; Juan Carlos Lopez-Talavera
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

2.  Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.

Authors:  Thierry Bizollon; Pierre Pradat; Jean-Yves Mabrut; Michelle Chevallier; Mustapha Adham; Sylvie Radenne; Jean-Christophe Souquet; Christian Ducerf; Jacques Baulieux; Fabien Zoulim; Christian Trepo
Journal:  Am J Transplant       Date:  2005-08       Impact factor: 8.086

3.  HCV-related fibrosis progression following liver transplantation: increase in recent years.

Authors:  M Berenguer; L Ferrell; J Watson; M Prieto; M Kim; M Rayón; J Córdoba; A Herola; N Ascher; J Mir; J Berenguer; T L Wright
Journal:  J Hepatol       Date:  2000-04       Impact factor: 25.083

4.  Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

Authors:  Amandeep K Shergill; Mandana Khalili; Stephanie Straley; Kathy Bollinger; John P Roberts; Nancy A Ascher; Norah A Terrault
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

5.  Kinetics of hepatitis C virus reinfection after liver transplantation.

Authors:  Kimberly A Powers; Ruy M Ribeiro; Keyur Patel; Stephen Pianko; Lisa Nyberg; Paul Pockros; Andrew J Conrad; John McHutchison; Alan S Perelson
Journal:  Liver Transpl       Date:  2006-02       Impact factor: 5.799

6.  Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.

Authors:  Raffaele Bruno; Paolo Sacchi; Valentina Ciappina; Cristina Zochetti; Savino Patruno; Laura Maiocchi; Gaetano Filice
Journal:  Antivir Ther       Date:  2004-08

7.  Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

Authors:  Ryan M Thomas; John J Brems; Grace Guzman-Hartman; Sherri Yong; Patricia Cavaliere; David H Van Thiel
Journal:  Liver Transpl       Date:  2003-09       Impact factor: 5.799

8.  Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

Authors:  Xavier Forns; Montserrat García-Retortillo; Trinidad Serrano; Anna Feliu; Francisco Suarez; Manuel de la Mata; Juan Carlos García-Valdecasas; Miquel Navasa; Antoni Rimola; Juan Rodés
Journal:  J Hepatol       Date:  2003-09       Impact factor: 25.083

Review 9.  Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation.

Authors:  Norah A Terrault
Journal:  Liver Transpl       Date:  2003-11       Impact factor: 5.799

10.  Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha.

Authors:  Scot D Henry; Herold J Metselaar; Richard C B Lonsdale; Alice Kok; Bart L Haagmans; Hugo W Tilanus; Luc J W van der Laan
Journal:  Gastroenterology       Date:  2006-08-14       Impact factor: 22.682

View more
  2 in total

1.  A combination procedure with thrombolytic therapy and balloon dilatation for portal vein thrombus enables the successful performance of antiviral therapy after a living-donor liver transplantation: report of a case.

Authors:  Koji Hamasaki; Susumu Eguchi; Mitsuhisa Takatsuki; Kensuke Miyazaki; Akihiko Soyama; Masaaki Hidaka; Kosho Yamanouchi; Yoshitsugu Tajima; Takashi Kanematsu
Journal:  Surg Today       Date:  2010-09-25       Impact factor: 2.549

2.  Evolution of living donor liver transplantation over 10 years: experience of a single center.

Authors:  Susumu Eguchi; Mitsuhisa Takatsuki; Masaaki Hidaka; Yoshitsugu Tajima; Takashi Kanematsu
Journal:  Surg Today       Date:  2008-08-28       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.